- Home
- SBS vs RPRX Comparison
SBS vs RPRX Comparison
Compare SBS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBS | RPRX |
|---|---|---|
| Founded | 1954 | 1996 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4B | 16.4B |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SBS | RPRX |
|---|---|---|
| Price | $22.98 | $39.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $45.75 |
| AVG Volume (30 Days) | 1.1M | ★ 3.3M |
| Earning Date | 11-10-2025 | 02-10-2026 |
| Dividend Yield | ★ 3.87% | 2.38% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.92 | 1.75 |
| Revenue | ★ $6,502,517,346.00 | $2,349,844,000.00 |
| Revenue This Year | N/A | $37.66 |
| Revenue Next Year | $14.07 | $2.34 |
| P/E Ratio | ★ $11.96 | $22.58 |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $14.48 | $29.66 |
| 52 Week High | $26.46 | $41.70 |
Technical Indicators
Market Signals| Indicator | SBS | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.26 | 49.50 |
| Support Level | $22.85 | $39.87 |
| Resistance Level | $24.80 | $40.58 |
| Average True Range (ATR) | 0.40 | 0.78 |
| MACD | -0.12 | -0.03 |
| Stochastic Oscillator | 19.03 | 34.46 |
Price Performance
Historical ComparisonAbout SBS Companhia de saneamento Basico
Companhia De Saneamento Basico Do Estado De Sao Paulo is engaged in the provision of basic and environmental sanitation services in the Sao Paulo State and supplies treated water and sewage services on a wholesale basis. The company operates in a single segment, which is Sanitation services.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.